These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 10592854)

  • 1. Use of placebo controls in an oral contraceptive trial: methodological issues and adverse event incidence.
    Redmond G; Godwin AJ; Olson W; Lippman JS
    Contraception; 1999 Aug; 60(2):81-5. PubMed ID: 10592854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The duration of response to norgestimate and ethinyl estradiol in the treatment of acne vulgaris.
    Olson WH; Lippman JS; Robisch DM
    Int J Fertil Womens Med; 1998; 43(6):286-90. PubMed ID: 9920537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Norgestimate and ethinyl estradiol in the treatment of acne vulgaris: a randomized, placebo-controlled trial.
    Redmond GP; Olson WH; Lippman JS; Kafrissen ME; Jones TM; Jorizzo JL
    Obstet Gynecol; 1997 Apr; 89(4):615-22. PubMed ID: 9083323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The association of serum androsterone glucuronide with inflammatory lesions in women with adult acne.
    Carmina E; Godwin AJ; Stanczyk FZ; Lippman JS; Lobo RA
    J Endocrinol Invest; 2002 Oct; 25(9):765-8. PubMed ID: 12398233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH; Gollnick H; Schellschmidt I
    Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatment.
    Thiboutot D; Archer DF; Lemay A; Washenik K; Roberts J; Harrison DD
    Fertil Steril; 2001 Sep; 76(3):461-8. PubMed ID: 11532465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical evidence of the endocrinological influence of a triphasic oral contraceptive containing norgestimate and ethinyl estradiol in treating women with acne vulgaris. A pilot study.
    Sator PG; Schmidt JB; Hönigsmann H
    Dermatology; 2003; 206(3):241-8. PubMed ID: 12673082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attenuation of mild hyperandrogenic activity in postpubertal acne by a triphasic oral contraceptive containing low doses of ethynyl estradiol and d,l-norgestrel.
    Lemay A; Dewailly SD; Grenier R; Huard J
    J Clin Endocrinol Metab; 1990 Jul; 71(1):8-14. PubMed ID: 2142494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter comparative trial of triphasic and monophasic, low-dose combined oral contraceptives.
    Dunson TR; McLaurin VL; Aguayo EL; de Silva P; Calventi V; Gerais AS; Serani RG
    Contraception; 1993 Jun; 47(6):515-25. PubMed ID: 8334888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters.
    Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H
    Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of a triphasic combination oral contraceptive containing norgestimate/ethinyl estradiol on biochemical markers of bone metabolism in young women with osteopenia secondary to hypothalamic amenorrhea.
    Grinspoon SK; Friedman AJ; Miller KK; Lippman J; Olson WH; Warren MP
    J Clin Endocrinol Metab; 2003 Aug; 88(8):3651-6. PubMed ID: 12915650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of acne using a 3-milligram drospirenone/20-microgram ethinyl estradiol oral contraceptive administered in a 24/4 regimen: a randomized controlled trial.
    Maloney JM; Dietze P; Watson D; Niknian M; Lee-Rugh S; Sampson-Landers C; Korner P
    Obstet Gynecol; 2008 Oct; 112(4):773-81. PubMed ID: 18827119
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations.
    Rosenberg MJ; Meyers A; Roy V
    Contraception; 1999 Dec; 60(6):321-9. PubMed ID: 10715366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
    Hampton RM; Short M; Bieber E; Bouchard C; Ayotte N; Shangold G; Fisher AC; Creasy GW
    Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial.
    Notelovitz M; Kitchens CS; Khan FY
    Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of combined oral contraceptives containing norgestimate for acne vulgaris treatment: a review.
    Grandi G; Guariglia G; Facchinetti F
    Eur J Contracept Reprod Health Care; 2023 Jun; 28(3):184-191. PubMed ID: 37042197
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pituitary function and DHEA-S in male acne and DHEA-S, prolactin and cortisol before and after oral contraceptive treatment in female acne.
    Palatsi R; Reinilä M; Kivinén S
    Acta Derm Venereol; 1986; 66(3):225-30. PubMed ID: 2426899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
    Lucky AW; Koltun W; Thiboutot D; Niknian M; Sampson-Landers C; Korner P; Marr J
    Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.